The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated follow up of a randomized, double-blinded phase II study of ketoconazole (keto), hydrocortisone (HC), and anti-PSMA antibody J591 labeled with 177Lu or 111In in patients (pts) with high-risk non-metastatic (met) castration-resistant prostate cancer (M0 CRPC).
 
Abdul Baseet Arham
No Relationships to Disclose
 
Charlene Thomas
No Relationships to Disclose
 
Issa Castaneda
No Relationships to Disclose
 
Samuel Ruder
No Relationships to Disclose
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Cardinal Health; Castle Biosciences; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genzyme; Gilead Sciences; Janssen; Myovant Sciences; Novartis; Pfizer; Roche/Genentech; Seagen; TTC Oncology
Research Funding - Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Newlink Genetics
 
Leonard Appleman
Consulting or Advisory Role - AADi
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Epizyme (Inst); Exelixis (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Ipsen (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Seagen (Inst); Surface Oncology (Inst); Syncromune (Inst)
Other Relationship - Pfizer
(OPTIONAL) Uncompensated Relationships - Exelixis
 
Joseph Osborne
No Relationships to Disclose
 
George Philips
No Relationships to Disclose
 
Luke Nordquist
Stock and Other Ownership Interests - Clarity Pharmaceuticals
Travel, Accommodations, Expenses - Fusion Pharmaceuticals
 
Anishka D'souza
No Relationships to Disclose
 
Elizabeth Wulff-Burchfield
Stock and Other Ownership Interests - Immunomedics (I); Nektar (I)
Consulting or Advisory Role - Aptitude Health; Astellas Scientific and Medical Affairs Inc; AVEO; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Targeted Oncology
Research Funding - Acerta Pharma/AstraZeneca (Inst); Pfizer
Patents, Royalties, Other Intellectual Property - Methods of use patent application has been submitted for the pharmaceutical product Osanetant, owned by Acer Therapeutics.
 
Edwin Posadas
Consulting or Advisory Role - Bayer
Speakers' Bureau - Bayer
Research Funding - PFizer (Inst)
Patents, Royalties, Other Intellectual Property - Patent on NanoVelcro Assay for CTCs in prostate cancer
Expert Testimony - Shook, Hardy & Bacon L.L.P.
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Paul Christos
No Relationships to Disclose
 
Nabil Adra
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; EMD Serono; Exelixis; Merck; Sanofi
Research Funding - Exelixis (Inst); Genentech (Inst); Merck (Inst); Natera (Inst)
 
David Nanus
No Relationships to Disclose
 
Scott Tagawa
Stock and Other Ownership Interests - Convergent Therapeutics
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Ambrx; Amgen; Astellas Pharma; Bayer; Bicycle Therapeutics; Blue Earth Diagnostics; Boston Scientific; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Daiichi Sankyo; Dendreon; Endocyte; Exelixis; Genentech; General Electric; Genomic Health; Gilead Sciences; Hookipa Pharma; Immunomedics; Janssen; Karyopharm Therapeutics; Lantheus Medical Imaging; Medivation; Merck; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Regeneron; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar; TransThera Biosciences
Research Funding - Abbvie (Inst); Ambrx (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clarity Pharmaceuticals (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Janux Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); Telix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Immunomedics; Merck; Sanofi; Telix Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics